X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4167) 4167
pyrazines - therapeutic use (3052) 3052
bortezomib (2702) 2702
male (2286) 2286
female (1920) 1920
middle aged (1592) 1592
boronic acids - therapeutic use (1533) 1533
animals (1402) 1402
pyrazines - pharmacology (1362) 1362
pyrazines - administration & dosage (1313) 1313
aged (1249) 1249
oncology (1237) 1237
multiple myeloma - drug therapy (1205) 1205
adult (1136) 1136
antineoplastic agents - therapeutic use (1021) 1021
boronic acids - administration & dosage (931) 931
hematology (898) 898
treatment outcome (890) 890
antineoplastic combined chemotherapy protocols - therapeutic use (889) 889
pyrazines - adverse effects (781) 781
multiple myeloma (742) 742
boronic acids - pharmacology (667) 667
mice (644) 644
pharmacology & pharmacy (591) 591
apoptosis (576) 576
sitagliptin phosphate (571) 571
cancer (558) 558
boronic acids - adverse effects (495) 495
triazoles - therapeutic use (459) 459
cell line, tumor (450) 450
protease inhibitors - therapeutic use (448) 448
diabetes mellitus, type 2 - drug therapy (447) 447
therapy (444) 444
rats (442) 442
proteasome inhibitors (439) 439
antineoplastic agents - pharmacology (438) 438
apoptosis - drug effects (430) 430
care and treatment (430) 430
dexamethasone - administration & dosage (378) 378
drug therapy, combination (374) 374
thalidomide - analogs & derivatives (374) 374
aged, 80 and over (373) 373
research (373) 373
chemotherapy (372) 372
hypoglycemic agents - therapeutic use (367) 367
dose-response relationship, drug (350) 350
clinical trials as topic (346) 346
multiple-myeloma (346) 346
analysis (320) 320
thalidomide - therapeutic use (319) 319
drug therapy (315) 315
multiple myeloma - pathology (308) 308
dexamethasone (305) 305
thalidomide - administration & dosage (302) 302
thalidomide (294) 294
antineoplastic agents - adverse effects (273) 273
expression (271) 271
antineoplastic combined chemotherapy protocols - adverse effects (267) 267
medicine & public health (262) 262
recurrence (262) 262
endocrinology & metabolism (255) 255
transplantation (254) 254
dipeptidyl-peptidase iv inhibitors - therapeutic use (249) 249
sitagliptin (243) 243
stem-cell transplantation (243) 243
time factors (242) 242
health aspects (241) 241
survival (237) 237
nf-kappa-b (235) 235
prognosis (235) 235
activation (231) 231
multiple myeloma - therapy (225) 225
cells (223) 223
abridged index medicus (221) 221
dosage and administration (217) 217
type 2 diabetes (213) 213
hematology, oncology and palliative medicine (212) 212
rats, sprague-dawley (209) 209
retrospective studies (208) 208
disease models, animal (207) 207
antineoplastic agents - administration & dosage (206) 206
cell proliferation - drug effects (206) 206
proteasome inhibitor bortezomib (206) 206
drug administration schedule (205) 205
pyrazines - chemistry (204) 204
protease inhibitors - pharmacology (202) 202
dexamethasone - therapeutic use (201) 201
proteasome endopeptidase complex - metabolism (201) 201
medicine, general & internal (200) 200
trial (199) 199
pyrazines - pharmacokinetics (198) 198
drug resistance, neoplasm (197) 197
drug synergism (197) 197
hemic and lymphatic diseases (195) 195
multiple myeloma - complications (193) 193
proteins (193) 193
biochemistry & molecular biology (191) 191
cell biology (190) 190
combination (190) 190
lenalidomide (189) 189
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4512) 4512
Chinese (135) 135
French (108) 108
Japanese (100) 100
Italian (66) 66
German (65) 65
Spanish (34) 34
Czech (21) 21
Russian (18) 18
Polish (17) 17
Dutch (10) 10
Hungarian (10) 10
Portuguese (6) 6
Swedish (5) 5
Danish (4) 4
Norwegian (4) 4
Hebrew (2) 2
Slovak (2) 2
Turkish (2) 2
Finnish (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Head & Neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No effective systemic treatment... 
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | SURGERY | HISTONE DEACETYLASE INHIBITOR | SUBEROYLANILIDE HYDROXAMIC ACID | ABL TYROSINE KINASE | PROTEASOME INHIBITION | CELL-CYCLE ARREST | VALPROIC ACID | DEPSIPEPTIDE FR901228 | PHASE-II TRIAL | OTORHINOLARYNGOLOGY | IMATINIB MESYLATE | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
Diabetes and Metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
Cancer cell, ISSN 1535-6108, 2012, Volume 22, Issue 3, pp. 345 - 358
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting... 
DEUBIQUITINATING ENZYME | INACTIVATION | PROTEIN | THERAPY | ONCOLOGY | MDM2 | DEGRADATION | MECHANISMS | HAUSP | CANCER | P53 REGULATION | CELL BIOLOGY | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Molecular Sequence Data | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Thalidomide - pharmacology | Boronic Acids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Protease Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Multiple Myeloma - enzymology | Protease Inhibitors - therapeutic use | Proto-Oncogene Proteins c-mdm2 - metabolism | Ubiquitin Thiolesterase - antagonists & inhibitors | Bortezomib | Cyclin-Dependent Kinase Inhibitor p21 - antagonists & inhibitors | Thiophenes - pharmacology | Random Allocation | Mice, SCID | Ubiquitin Thiolesterase - genetics | Xenograft Model Antitumor Assays | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Mice | Thalidomide - therapeutic use | Pyrazines - pharmacology | Ubiquitin-Specific Peptidase 7 | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Medical colleges | Dexamethasone | Proteases | Analysis | Multiple myeloma | Lymphomas | Apoptosis
Journal Article
Blood, ISSN 0006-4971, 08/2014, Volume 124, Issue 9, pp. 1404 - 1411
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2/2015, Volume 23, Issue 2, pp. 513 - 524
...Support Care Cancer (2015) 23:513 – 524 DOI 10.1007/s00520-014-2408-8 REVIEW ARTICLE Current use of drugs affecting the central nervous system for chemotherapy... 
Pain Medicine | Anticonvulsants | Chemotherapy | Nursing | Rehabilitation Medicine | Medicine & Public Health | Antidepressants | Oncology | Peripheral neuropathy | Nursing Management/Nursing Research | Cancer | CONTROLLED-TRIAL | MANAGEMENT | EFFICACY | PREVENTION | GABAPENTIN | OXALIPLATIN-RELATED NEUROTOXICITY | PAIN | ONCOLOGY | COLORECTAL-CANCER | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | QUALITY-OF-LIFE | Thiophenes - therapeutic use | Peripheral Nervous System Diseases - chemically induced | Humans | Boronic Acids - adverse effects | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Epothilones - therapeutic use | Boronic Acids - therapeutic use | Epothilones - adverse effects | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Taxoids - adverse effects | Thalidomide - adverse effects | Bortezomib | Carbamazepine - analogs & derivatives | Vinca Alkaloids - adverse effects | Anticonvulsants - therapeutic use | Carbamazepine - therapeutic use | Vinca Alkaloids - therapeutic use | Neuralgia - drug therapy | Neoplasms - drug therapy | Antidepressive Agents - therapeutic use | Venlafaxine Hydrochloride | Pyrazines - adverse effects | Central Nervous System - drug effects | Cyclohexanols - therapeutic use | Duloxetine Hydrochloride | Amitriptyline - therapeutic use | Thalidomide - therapeutic use | Peripheral Nervous System Diseases - drug therapy | Drugs | Cancer patients | Care and treatment | Central nervous system | Nervous system | Drug therapy | Neuropathology
Journal Article
Journal Article